Health TrialsbyHealthPanel

Voiding and Erectile Function After Retroperitoneal Lymph Node Dissection for Testicular Cancer

ConditionTesticular Cancer
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexMale
Age18+
SponsorJagiellonian University

About this trial

This study aims to evaluate how retroperitoneal lymph node dissection (RPLND), a surgical treatment for testicular cancer, may affect urinary and sexual functions in men. RPLND involves the removal of lymph nodes from the abdominal area and is sometimes necessary in patients who are not eligible for chemotherapy or who have residual disease after chemotherapy. While this surgery is known to carry a risk of affecting ejaculation, its potential impact on other areas such as urination or erection is not well understood.

The study will prospectively follow adult men undergoing RPLND. It will assess changes in lower urinary tract symptoms, urine flow, ejaculation, erection, and overall quality of life before surgery and during follow-up visits up to 6 months after the operation. Patients will complete standardized questionnaires and undergo simple, non-invasive tests such as urine flow measurement.

By identifying how RPLND may influence urinary and sexual health, this study seeks to improve understanding of the full range of effects of this treatment. The findings may help clinicians better inform patients before surgery and support improved post-operative care.

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

Adult male with testicular cancer undergoing retroperitoneal lymph node dissection (RPLND)

Disqualifiers

History of RPLND

Lack of consent

Trial population

Adult males with testicular cancer undergoing retroperitoneal lymph node dissection (RPLND)

Trial design

Design model

Cohort

Time perspective

Prospective

Treatments tested in this trial

  • Uroflowmetry and questionnaires

    Diagnostic test

    Uroflowmetry - urine flow assessment Questionnaires: IPSS, ICIQ-MLUTS, IIEF-5, MSHQ-EjD, EQ-5D-5L

Treatment groups

20 Participants
are divided into 1 treatment group
Group A: Adult men with testicular cancer undergoing retroperitoneal lymph node dissection1 intervention

Trial outcomes

Primary outcomes

1

Change in maximal urine flow (Qmax) in uroflowmetry before and after RPLND surgery

Change in maximal urine flow (Qmax) in uroflowmetry before and after RPLND surgery

Time frame
6 months
2

Change in post-void residual volume (PVR) before and after RPLND surgery

Change in post-void residual volume (PVR) before and after RPLND surgery

Time frame
6 months
3

Change in total IPSS score before and after RPLND surgery

Patients will complete International Prostate Symptom Score (IPSS) questionnaire to assess urinary function before and after surgery

Time frame
6 months
4

Change in ICIQ-MLUTS score before and after RPLND surgery

Patients will complete Incontinence Questionnaire - Male Lower Urinary Tract Symptoms - ICIQ-MLUTS questionnaire to assess urinary function before and after surgery

Time frame
6 months

Secondary outcomes

1

Change in IIEF-5 questionnaire before and after RPLND surgery

Patients will complete International Index of Erectile Function - IIEF-5 questionnaire before and after surgery to assess erectile function

Time frame
6 months
2

Change in MSHQ-EjD questionnaire before and after RPLND surgery

Patients will complete Male Sexual Health Questionnaire Ejaculatory Dysfunction - MSHQ-EjD questionnaire before and after surgery to assess erectile function

Time frame
6 months

Other outcomes

Sponsors and contacts

Click on the lead sponsor to view all of their trials.

Jagiellonian University

Lead sponsor

Source ClinicalTrials.gov
Apply now